{"title": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) - Full Text View - ClinicalTrials.gov", "author": null, "url": "https://clinicaltrials.gov/ct2/show/NCT03897881", "hostname": "clinicaltrials.gov", "description": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) - Full Text View.", "sitename": "ClinicalTrials.gov", "date": "2019-04-01", "cleaned_text": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. | |ClinicalTrials.gov Identifier: NCT03897881| | | Recruitment Status : Recruiting First Posted : April 1, 2019 Last Update Posted : May 16, 2023 - Study Details [Tabular View](/ct2/show/record/NCT03897881) [No Results Posted](/ct2/show/results/NCT03897881) Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection Study Date :||September Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner. | Drug: mRNA-4157 | Individualized Neoantigen Therapy Biological: Pembrolizumab Intravenous Active Comparator: Pembrolizumab | Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner. | Biological: Pembrolizumab | Intravenous infusion - Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging [ Time Frame: Up to 5 years ]RFS is defined as the time between the date of first dose of pembrolizumab and the date of recurrence (local, regional, or distant metastasis), new primary melanoma, or death (whatever the cause), whichever occurs first. - Distant Metastasis-Free Survival (DMFS), Assessed Using Radiological Imaging [ Time Frame: Up to 5 years ]DMFS is defined as the time between the date of first dose of pembrolizumab and the date of the first distant metastasis or the date of death (whatever the cause), whichever occurs first. - Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms) ] - Number of Participants Who Discontinued Due to AEs [ Time Frame: Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms) ] Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies.](/ct2/about-studies/learn) |Ages Eligible for Study:||18 Years and older (Adult, Older Adult)| |Sexes Eligible for Resectable cutaneous melanoma metastatic to a lymph node and at high risk of recurrence - Complete resection within 13 weeks prior to the first dose of pembrolizumab - Disease free at study entry (after surgery) with no loco-regional relapse or distant metastasis and no clinical evidence of brain metastases - Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for sequencing - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 - Normal organ and marrow function reported at screening Key Exclusion Criteria: - Prior malignancy, unless no evidence of that disease for at least 5 years prior to study entry - Prior systemic anti-cancer treatment (except surgery and interferon for thick primary melanomas. Radiotherapy after lymph node dissection is permitted) - Live vaccine within 30 days prior to the first dose of pembrolizumab - Transfusion of blood or administration of colony stimulating factors within 2 weeks of the screening blood sample - Active autoimmune disease - Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab - Solid organ or allogeneic bone marrow transplant - Pneumonitis or a history of (noninfectious) pneumonitis that required steroids - Prior interstitial lung disease - Clinically significant heart failure - Known history of human immunodeficiency virus (HIV) - Known active hepatitis B or C - Active infection requiring treatment To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): Melanoma Pembrolizumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action "}